Alectinib (AlecensaTM) is a second-generation, highly selective and potent central nervous system (CNS)-active ALK inhibitor that inhibits tumor proliferation, with specific activity against several ALK mutations [6,7,8]. The gene discussed is ALK; the disease is neoplasm.